PR

Dr. Noah Biotech and France's Dassault Systèmes launch full-scale collaboration on BIOVIA-based AI novel drug development

- Selected for the 2025 ‘Daonda’ Global Enterprise Collaboration Program by the Korea Institute of Startup & Entrepreneurship Development (KISED) under the Ministry of SMEs and Startups

- Accelerating rare disease treatment development and advancing the ‘ARK platform’ through strategic global partnerships

[by Kang, In Hyo] Dr. Noah Biotech, a company specializing in AI-based new drug development, announced on May 30 that it has been officially selected for the 2025 Global Enterprise Collaboration Program, ‘Daonda,’ organized by the Korea Institute of Startup & Entrepreneurship Development (KISED) under the Ministry of SMEs and Startups.

Accordingly, Dr. Noah Biotech will collaborate with Dassault Systèmes, a global leader in 3D simulation technology, to enhance its AI-based novel drug development platform, ‘ARK,’ and develop candidate substances for the treatment of rare diseases.

Headquartered in France, Dassault Systèmes is a leading AI-driven virtual twin company that offers solutions in 3D design, simulation, manufacturing/production, and marketing across diverse industries, including automobiles, aerospace, shipbuilding, and life sciences and healthcare. Among its offerings, the ‘BIOVIA’ solution in the life sciences sector is a core technology widely used by global pharmaceutical companies for molecular modeling, experimental data management, and simulation-based new drug design.

Through this collaboration, Dr. Noah Biotech intends to carry out verification research on AI-driven new drug development using Dassault Systèmes’ BIOVIA solution, with a particular focus on evaluating the predictive accuracy and practical applicability of its ARK platform in elucidating ‘drug-disease action mechanisms.’ Upon completion of the project, the company plans to explore various collaborative models, including the potential integration of BIOVIA functionalities into ARK, based on the outcomes of the verification process.

This project targets ‘multiple sclerosis (MS)’ as the primary indication, with the dual objectives of enhancing the analytical capabilities of the ARK platform and identifying potential therapeutic candidates. Additionally, Dr. Noah Biotech is preparing to enter clinical trials following the U.S. Food and Drug Administration (FDA)’s approval of its Phase 1 Investigational New Drug (IND) application for ‘NDC-011,’ a candidate treatment for amyotrophic lateral sclerosis (ALS), formerly known as Lou Gehrig’s disease. The company is actively pursuing global expansion in the field of rare neurological disorders.

“BIOVIA is a software portfolio that digitalizes and streamlines the R&D process in the life sciences sector and is widely adopted by leading global pharmaceutical companies,” said Lee Ji-hyun, CEO of Dr. Noah Biotech. “This collaboration represents an opportunity to align ourselves with world-class technology-based companies. We remain committed to refining and advancing the functionalities of ARK to establish it as a reliable platform in the global market,” she added.

Leveraging the technological achievements achieved through this project, Dr. Noah Biotech intends to actively pursue business diversification strategies, including co-development with global pharmaceutical firms, technology licensing, and the provision of integrated non-clinical services.

https://www.thebionews.net/news/articleView.html?idxno=15458